why choose us

First received: September 30, 2022

Clinical Trial: Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Open-label Study to Determine the Central Nervous System Efficacy of Capmatinib in NSCLC Patients With Brain Metastases With cfDNA Positive MET Alterations

Brief Summary: This is a phase II single-arm open label trial to evaluate the intracranial efficacy of capmatinib in advanced stage NSCLC with asymptomatic BM with positive MET amplification or MET?ex14 detected on cfDNA.

Read more